New guidelines on treating obesity

The Endocrine Society has issued clinical guidance on the pharmacological treatment of obesity. In the past two years the FDA has approved four new anti-obesity drugs  – lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide. Medications approved for chronic weight management can be useful adjuncts to lifestyle change for patients who have been unsuccessful with diet and exercise alone, the ...

Already a member?

Login to keep reading.

© 2021 the limbic